Tag: Senseonics
In brief: CPAP’s adherence assumption, CGM’s benefits, Shaq’s sleep apnea
June 12, 2026HME News Staff
ORLANDO, Fla. – Many insurers stop covering continuous positive airway pressure (CPAP) devices if patients don’t use them regularly in the first 90 days. But new research presented at the ATS 2026 International Conference shows that many patients who initially struggle to meet these early-use thresholds do go on to use and benefit from CPAP therapy.
The findings challenge long-held assumptions that poor early use predicts long-term CPAP use, said first author Dennis Hwang, MD, a sleep...
Senseonics, Welldoc partner to develop mobile app for Eversense 365
June 10, 2026HME News Staff
GERMANTOWN & COLUMBIA, Md. – Senseonics and Welldoc have announced a strategic partnership to develop a new custom mobile application for the Eversense 365. The next-generation app will maintain all existing features that patients currently benefit from, alongside new features to enhance user experience and facilitate better integration with popular digital health tools. As part of this, the new and improved Eversense 365 app will facilitate seamless integration with Apple Health and Google...
Senseonics launches Eversense 365 in Sweden, other countries to follow
April 27, 2026HME News Staff
GERMANTOWN, Md. – Senseonics Holdings has launched its Eversense 365 CGM system in Europe, following CE Mark approval in January. The Eversense 365 is now available to the first patients in Sweden, with launches to follow in Germany, Spain, and Italy during the coming weeks.The next-generation Eversense 365 doubles sensor lifespan from the previously available Eversense E3, from six months to a full year, and delivers key improvements such as reducing the frequency of calibrations from once...
Senseonics to enter EU markets with Eversense 365 CGM system
February 2, 2026HME News Staff
GERMANTOWN, Md. - Senseonics Holdings has announced CE Mark approval for the Eversense 365 CGM system, paying the way for the company to enter the German, Italian, Spanish and Swedish markets in the coming months. “European approval for Eversense 365 represents the latest achievement in our long-term growth strategy for Senseonics and expands our total addressable market by over 30 million patients living with diabetes...
Senseonics announces first patients using integrated twiist AID system, Eversense 365 CGM
January 13, 2026HME News Staff
GERMANTOWN, Md. - Senseonics and Sequel MedTech have launched the integration of their products with the first patients receiving a Sequel twiist automated insulin delivery (AID) system paired with the implantable Eversense 365 continuous glucose monitor (CGM). The companies say pairing twiist with Eversense 365 is the first time the world’s only one year CGM system has been integrated with an...
Senseonics, Ascensia hit sweet spot
March 3, 2025HME News Staff
PARSIPPANY, N.J. – Senseonics Holdings and Ascensia Diabetes Care have integrated SweetSpot with the Eversense 365 Continuous Glucose Monitoring (CGM) System in the U.S., providing endocrinology practices that partner with them the ability to continue to improve patient care by seamlessly and regularly reviewing data from patients. SweetSpot combines a centralized software platform for managing diabetes device data with wrap-around clinical support services, including a virtual team...
Senseonics files for CE Mark
February 13, 2025HME News Staff
GERMANTOWN, Md. – Senseonics Holdings has filed for CE Mark registration for the Eversense 365 CGM system, paving the way for commercialization in European Union countries by Acensia Diabetes Care. “Completing the CE Mark submission for Eversense 365 brings us a step closer to improving lives and health outcomes for patients in Europe,” said Tim Goodnow, president and CEO of Senseonics. “Given the success we have had to date with the U.S. launch, we look forward to the opportunity...
Senseonics, Ascensia launch one-year CGM system
September 17, 2024HME News Staff
GERMANTOWN, Md., and PARSIPPANY, N.J. – Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system. “The approval of Eversense 365 represents a significant leap in CGM innovation,” said Tim Goodnow, PhD, president and CEO of Senseonics. “Extending sensor longevity to a full year, coupled with seamless device connectivity and a high level of accuracy, provides...
Ascensia extends PASS program
March 14, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings will extend the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversense E3 CGM System more affordably, the program offers major savings for eligible individuals looking to experience the unique benefits of the only long-term CGM system available. Eligible individuals will pay only $99 out of pocket for an unlimited number of six-month Eversense E3 systems under...
Ascensia announces coverage expansion for CGM system
February 12, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings have announced that Medicare has significantly expanded access to the Eversense E3 CGM System with the implementation of local coverage determinations that provide access to implantable CGM for basal-only patients. Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple inulin administrations per day. Coverage has also been updated...